GENA-104A16 

GENA-104A16 is a humanized monoclonal antibody targeting CNTN4, with multiple functions including immunostimulation, cytotoxicity and immunoregulation. By binding to CNTN4, GENA-104A16 blocks its interaction with APP, thereby restoring T cell function, inducing tumor cell death and regulating tumor-infiltrating immune cell populations. GENA-104A16 also exerts topoisomerase I inhibitory activity via the payload Exatecan (HY-13631). GENA-104A16 can be used in research related to colon cancer liver metastasis and other CNTN4-expressing solid tumors^{[1][2][3][4][5]}.

Human

GENA-104A16 potently kills CNTN4-positive cancer cells while exhibiting low Fcγ receptor-mediated cytotoxicity, an advantageous safety feature for antibody-drug conjugates^[1].
GENA-104A16 induces CNTN4-positive tumor cell death via multiple mechanisms and enhances T cell-mediated cytotoxicity through immune checkpoint blockade^[1].
GENA-104A16 increases T cell-mediated cytotoxicity against CNTN4-expressing human osteosarcoma U2OS cells in co-culture, with this effect dependent on CNTN4 expression by the cancer cells^[2].
GENA-104A16 restores T cell proliferation, activation, cytokine release, and cytotoxic killing activity against human CNTN4-expressing cancer cell lines^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GENA-104A16 exerts anti-tumor and immune-modulatory effects in CT26/CNTN4 syngeneic mice, increasing total tumor-infiltrated immune cells 2-fold, CD4⁺ T cells 4-fold, and CD8⁺ T cells 1.5-fold while reducing Treg cell populations and restoring cytokine secretion^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

152330  [NCBI]

Q8IWV2

CNTN4

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cha M Y, Yu H, Kim H, et al. Preclinical development of GENA-104 ADC, an exatecan-based novel antibody-drug conjugate targeting CNTN4, for solid tumors[J]. Cancer Research, 2026, 86(7_Supplement): 4443-4443.

  [2]. Cha M Y, Yu H, Jeon B N, et al. Novel immune checkpoint inhibitor: In vivo and in vitro efficacy of anti-CNTN4 antibody, GENA-104A16 in the models with increased CNTN4 expression[J]. Cancer Research, 2023, 83(7_Supplement): 1868-1868.

  [3]. Cha M Y, yu H, Jeon B N, et al. Novel immune checkpoint protein CNTN4 and the preclinical efficacy of affinity matured anti-CNTN4 antibody GENA-104A16[J]. Cancer Research, 2022, 82(12_Supplement): 2862-2862.

  [4]. Cha M Y, Jeon B N, Kang H, et al. Activation of transcription factors, p65 and NFATc1, mediated by WNT5a, induces up-regulation of novel immune checkpoint CNTN4 expression[J]. Cancer Research, 2023, 83(7_Supplement): 6382-6382.

  [5]. Yu H, Lee T, Kim G, et al. Immunostimulatory effects of GENA-104A16, a monoclonal anti-CNTN4 antibody, on tumor-infiltrating lymphocytes in a colon cancer liver metastasis model[J]. Cancer Research, 2025, 85(8_Supplement_1): 4790-4790.